AbCellera’s stock price sank for years after it went public but has recently taken off. The company struggled as its one-time rush of pandemic money dried up, but investors are now excited again because it is signing big new deals to help drug companies find future medicines more quickly.
What does it do?
AbCellera Biologics is a growth-stage biotech company that earns money by discovering new antibodies for pharmaceutical partners in exchange for milestone payments and future royalties. The company uses its AI-driven technology stack to search the immune systems of humans and animals for rare antibodies that can be turned into drugs. Instead of developing these drugs itself, which is expensive and risky, AbCellera performs the early discovery work and then hands the "recipe" to a partner like Eli Lilly or Regeneron. These partners handle the multi-year clinical trials and manufacturing, while AbCellera keeps a percentage of any eventual sales.
Where does revenue come from?
The majority of current revenue comes from research fees and milestone payments, though the long-term goal is for royalties to dominate the mix. Research fees are paid upfront to use the platform, while milestones are bonuses triggered when a partner moves a drug into a new phase of human testing. Geographically, most revenue is generated through partnerships with major global pharmaceutical companies based in the United States and Europe.
Revenue Breakdown
Revenue by Geography
Who are its customers?
AbCellera serves a total of 104 partner-initiated programs with downstreams, ranging from the world's largest pharmaceutical giants to small, venture-backed biotech startups. As of the end of 2025, the company has successfully moved 19 molecules into clinical trials, providing a clear track record that its discovery engine produces viable drug candidates. The customer base is highly concentrated among professional drug developers who pay for access to AbCellera’s specialized technology to speed up their own internal research pipelines. This model allows AbCellera to diversify its risk across hundreds of different disease targets, from cancer to autoimmune conditions, without the burden of running its own clinical trials.
What gives it staying power?
Its staying power comes from the sheer speed and depth of its discovery engine, which uses machine learning to screen millions of cells in days. This technical edge creates high switching costs, as partners who integrate AbCellera’s data into their research programs are unlikely to restart discovery elsewhere.
Where is it headed?
The company is shifting toward "co-development," where it takes on more cost and risk in exchange for much larger ownership stakes in the drugs it discovers. Management is using its $533 million cash reserve to build internal manufacturing and laboratory facilities. This move is designed to capture more of the value chain and move the company beyond being just a service provider.
Revenue is beginning to stabilize at around $80 million annually as the company works through the post-COVID trough. After a massive windfall from COVID-19 antibody royalties in 2021 and 2022, the business is now rebuilding its baseline through a diversified portfolio of non-COVID discovery programs.
Cash generation remains deeply negative, with a free cash flow burn of $170 million last year to fund aggressive lab and facility expansion. This divergence from earnings is intentional, as the company is investing heavily in property and equipment to support its new co-development strategy.
The balance sheet is exceptionally strong with $533 million in total cash and marketable securities and very little debt. This provides AbCellera with several years of runway to fund operations even without a major new royalty stream, serving as a critical safety net in a capital-intensive industry.
AbCellera is a financially resilient but currently loss-making business that is successfully transitioning away from its reliance on a single pandemic-era product.
The clinical pipeline is expanding, with 19 molecules now in human trials compared to 16 a year ago. This progress is the most direct evidence that the discovery engine is functioning and that partners are successfully moving these candidates toward potential commercialization.
The annual cash burn rate is the most critical factor to track while the company waits for a new royalty stream. If the co-development strategy takes longer than expected to produce a winner, the company may eventually need to raise more capital or slow its expansion.
The antibody discovery market is a subset of the $200 billion biopharma R&D market, growing at double digits as drugs shift from simple chemicals to complex biologics. The industry is shaped by the structural reality that drug discovery is becoming harder and more expensive, forcing pharma companies to outsource the most technical parts of research. AbCellera stands as a high-end platform player in this market, positioned to benefit as biologics continue to take share from traditional pills over the next decade.
The competitive dynamic is centered on technical precision and speed rather than price. Barriers to entry are high because of the massive data and specialized hardware needed to screen immune systems at scale, which protects established players from new entrants.
Adimab is the most dangerous threat, as it has a similar long-standing reputation for antibody discovery and already has dozens of drugs in the clinic. Schrodinger competes for the same R&D dollars by using software to simulate drug interactions, offering a different technical path to the same goal. The primary threat is the risk of a "commodity trap" if newer AI models make basic antibody discovery significantly cheaper for everyone.
AbCellera is currently holding its ground by expanding its cumulative program count and clinical pipeline. The company added eight new partner-initiated programs last year, proving that its platform remains in high demand despite rising competition.
The primary protection is its intellectual property, specifically the combination of microfluidics and machine learning that allows it to find "needle in a haystack" antibodies. This technology acts as a narrow moat because it is difficult to replicate the proprietary data models the company has built over a decade of searches.
The 79% gross margins and the steady expansion of molecules in clinical trials prove the business model has fundamental value. However, the lack of recurring revenue outside of lumpy milestones means the moat is not yet wide enough to protect against a prolonged dry spell in drug approvals.
The moat is currently stable, and the single most important signal will be whether the first wave of non-COVID molecules can reach the late-stage trials required for significant royalty payments. The platform works in the lab, but its true strength is still being tested in the clinic.
Scaled to 19 clinical molecules but revenue remains lumpy post-COVID.
Retained $533M in cash while building large-scale discovery infrastructure.
Founder Carl Hansen maintains a large personal stake and leads the company's vision.
Capital Allocation Track Record
Carl Hansen is a founder-CEO who has demonstrated exceptional technical vision and the ability to attract top-tier global pharmaceutical partners. Unlike many biotech leaders who over-promote unproven science, Hansen has prioritized building a massive cash buffer and tangible infrastructure, which gives the company the strategic independence to survive long development cycles. His judgment was validated by the speed at which the company delivered its COVID-19 treatment, a feat of engineering that proved the platform can perform under extreme pressure.
The primary governance risk is that the company’s future is deeply tied to the strategic vision of its founder, with a board that is closely aligned with management. While the technical bench is deep, a departure of Hansen would likely trigger significant volatility in the strategy to move toward co-development. However, the high insider ownership and the absence of value-destructive acquisitions suggest that management is treating shareholder capital with the same caution they would their own.
The business is expected to remain in a heavy investment phase with significant EPS losses until at least 2030 as it prioritizes building its clinical pipeline. Revenue is projected to climb as early-stage programs reach commercial milestones and the first non-COVID royalties begin to contribute meaningfully toward the end of the decade.
Portfolio maturation triggers the first major non-COVID royalty streams. As more of the 19 clinical molecules reach the market, AbCellera could begin receiving high-margin royalties that require zero additional labor or cost.
Co-development programs yield higher ownership stakes in blockbuster drugs. By taking on more research costs, AbCellera can secure much larger royalty percentages, fundamentally changing its earnings profile.
AI platform enhancements shorten the discovery cycle even further. Continuous improvements to the machine learning stack could attract a new wave of partners looking to shave years off their drug development timelines.
Clinical trial failures wipe out entire segments of the royalty pipeline. If the current molecules in the clinic fail to show efficacy, the company's projected future value could evaporate regardless of its technology.
Cash burn exhausts the safety net before royalties reach scale. The transition to co-development is expensive, and a prolonged market downturn could make it harder to replenish the $533 million cash pile.
Competing technologies commoditize the antibody discovery process. If open-source AI tools or cheaper competitors can replicate AbCellera's speed, the company's pricing power and royalty terms will collapse.
Below is our estimate of current and future fair value, with detailed reasoning and assumptions. Fair value is a judgment, not a fact, and other analysts will likely land on different numbers. Use it as one data point in your research, and apply your own discretion in any investing decision.
We use a Sum-of-the-Parts (SOTP) approach to value AbCellera, treating it as a diversified portfolio of biotech assets. This fits the business because its $500M+ cash pile and its research service engine have observable market values, while the long-term royalty potential functions like a "hidden" asset that a simple price-to-earnings ratio would fail to capture.
The headline math sums $421M in Net Cash, an $800M discovery platform, and a $1.2B royalty portfolio to reach an $8.00 fair value. A 10x revenue multiple for the platform sits between Schrödinger at 12x and Ginkgo Bioworks at 4x, reflecting AbCellera’s superior balance sheet but lumpy revenue growth. The $800M platform value is based on an $80M Next Twelve Months (NTM) revenue estimate derived from the current run-rate and the June 2026 Jazz Pharmaceuticals agreement. Summing these parts gives an equity value of $2.42B, which divided by 300.6M shares equals roughly $8.05.
A Price-to-Cash cross-check yields a "floor" value of $1.88 per share, representing the company's net liquidity and a minimal platform value. Subtracting $140M in debt from the $505M cash balance and adding the $56M June Jazz payment gives $421M in net cash ($1.40/share). Adding a baseline 2.0x revenue multiple for the platform—while assigning zero value to the 100+ drug royalties—gets us to $1.88. This suggests that at the current $7.58 price, investors are paying roughly $5.70 per share for the long-term royalty pipeline, a valuation we consider reasonable given the portfolio's breadth.
We're assuming the antibody discovery platform earns a 10x EV/Revenue multiple. This sits between software-like multiples and biotech service peers, reflecting the high scalability of the lab infrastructure once it moves past the current heavy investment phase. Current TTM revenue of ~$80M suggests a "base" platform value of $800M.
We're assuming the 100+ program royalty portfolio is currently worth approximately $1.2 billion. This equates to roughly $12M per "shot on goal," which is conservative given that early-stage oncology molecules in Phase 1 often command $50M+ in private market licensing value. As these programs move toward Phase 2, this per-program value should naturally appreciate.
We're assuming AbCellera maintains a "Net Cash" position of at least $400 million through 2027. The $56M upfront payment from the June 2026 Jazz Pharmaceuticals deal is a critical proof point that AbCellera can use its platform to generate non-dilutive capital to offset its operating losses while waiting for long-term royalties to mature.
The biggest risk is the "burn rate" of the $505 million cash pile before the royalty portfolio generates meaningful cash flow. If net losses persist at ~$45M per quarter without new upfront payments, the cash buffer disappears in less than three years. This would likely force a dilutive share offering at a low valuation, potentially knocking $2.50 to $3.00 off the per-share fair value. Watch the "Total cash and marketable securities" line quarterly for any drop below $350M.
Bear case ($5): Quarterly cash burn accelerates to more than $65M for two consecutive quarters without new upfront deal payments; or Clinical failure or program termination of ABCL635 results in a multi-year delay to the first internal commercial royalty stream.
Bull case ($13): First commercial royalty milestone from a legacy partner program exceeds $25M in a single quarter, proving the revenue model; or Jazz Pharmaceuticals collaboration achieves its first $100M developmental milestone within the next 18 months.
Clearthesis wrote this report from 36 sources, including SEC filings, industry research, and recent news.
How did you like this thesis?
Your feedback helps us make reports better for you
© 2026 Clearthesis.ai · Report generated on July 1, 2026
This is an AI-generated analysis for informational purposes only and does not constitute financial advice. Data and analysis may not reflect recent developments if viewed significantly after the generation date. Always conduct your own due diligence before making any investment decisions.
The market is leaning bullish because AbCellera is successfully pivoting its business model from a single viral success to a massive, diversified engine for drug discovery. The company recently secured a high-value partnership with Jazz Pharmaceuticals, proving its technology can reliably attract industry leaders to share in long-term royalty payments from over 100 different clinical programs.
Skeptics think that relying on future royalties makes the company a fragile bet that may never generate sustainable profits. They worry that the long wait for these drugs to succeed in clinical trials means the company is burning through its cash pile while failing to prove it can consistently turn its discovery process into commercial reality.